Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHuPH20 with Insulin Lispro and Regular Insulin in T2DM
NCT00916357Phase 2Completed
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Jul 2009
- Primary completion
- Nov 2009
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hyaluronidase in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Halozyme Therapeutics, Inc. Primary endpoint: Postprandial Glucose Excursion Following a Liquid Meal. Started Jul 2009; status: completed.
02
Drugs
hyaluronidase
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00916357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00916357.